News
AVIR
3.940
-1.50%
-0.060
Weekly Report: what happened at AVIR last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at AVIR last week (0422-0426)?
Weekly Report · 04/29 09:09
Weekly Report: what happened at AVIR last week (0415-0419)?
Weekly Report · 04/22 09:09
Weekly Report: what happened at AVIR last week (0408-0412)?
Weekly Report · 04/15 09:08
Weekly Report: what happened at AVIR last week (0401-0405)?
Weekly Report · 04/08 09:09
Weekly Report: what happened at AVIR last week (0325-0329)?
Weekly Report · 04/01 09:08
Weekly Report: what happened at AVIR last week (0318-0322)?
Weekly Report · 03/25 09:08
Weekly Report: what happened at AVIR last week (0311-0315)?
Weekly Report · 03/18 09:08
Weekly Report: what happened at AVIR last week (0304-0308)?
Weekly Report · 03/11 09:08
Weekly Report: what happened at AVIR last week (0226-0301)?
Weekly Report · 03/04 09:08
Atea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory Risks
TipRanks · 03/01 06:07
U.S. RESEARCH ROUNDUP-Okta, Salesforce, Sarepta Therapeutics
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Okta, Salesforce and Sarepta Therapeutics among companies with revised targets. Oka's stock rises; Salesforce's falls to $355; Universal Health Services rises to $192.
Reuters · 02/29 07:06
Atea Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Atea Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 47 cents per share. The mean expectation of four analysts was for a loss of 50 cents. Reported revenue was zero; analysts expected zero; shares rose by 49.5% this quarter.
Reuters · 02/29 02:27
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals reported its Q4 earnings on February 28. The company beat estimates by 6.0%. The company's revenue was down $0 from the same period last year. Atea pharmaceuticals is expected to report its earnings on Wednesday, February 28 at 4:05pm.
Benzinga · 02/28 21:35
Atea Pharmaceuticals Q4 2023 GAAP EPS $(0.47) Beats $(0.51) Estimate
Benzinga · 02/28 21:31
Atea Pharmaceuticals GAAP EPS of -$0.47 beats by $0.03
Seeking Alpha · 02/28 21:28
Atea Pharmaceuticals Earnings Preview
Atea Pharmaceuticals is set to give its latest quarterly earnings report on Wednesday. Analysts estimate the company will report an earnings per share of $-0.50. Last quarter the company beat EPS by $0.08. Shares of Atea pharmaceuticals were trading at $4.32 as of February 26.
Benzinga · 02/27 20:01
Weekly Report: what happened at AVIR last week (0219-0223)?
Weekly Report · 02/26 09:09
Weekly Report: what happened at AVIR last week (0212-0216)?
Weekly Report · 02/19 09:09
Noteworthy Thursday Option Activity: CROX, GEO, AVIR
NASDAQ · 02/15 20:18
More
Webull provides a variety of real-time AVIR stock news. You can receive the latest news about Atea Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AVIR
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.